Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in non-small-cell lung cancer

Wang,Yadi; Ha,Minwen; Liu,Jingsong; Li,Ping; Zhang,Wenlu; Zhang,Xuan

doi:10.3892/ol.2015.4003

Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in non-small-cell lung cancer

Authors:
- Yadi Wang
- Minwen Ha
- Jingsong Liu
- Ping Li
- Wenlu Zhang
- Xuan Zhang
View Affiliations

Affiliations: Department of Oncology, Third Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China, Department of Oncology, First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China, Department of Heart Surgery, First Affiliated Hospital of Xuzhou Medical College, Jinzhou, Liaoning 121000, P.R. China
Published online on: December 4, 2015 https://doi.org/10.3892/ol.2015.4003
Pages: 984-990
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to address the pharmacogenetic role of BAG1 in platinum‑based chemotherapy in advanced non-small-cell lung cancer (NSCLC) and in cultured human lung adenocarcinoma A549 cells. A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. Additionally, in vitro cultured A549 cells were treated with cisplatin in the presence or absence of tunicamycin. Cell proliferation was determined by MTT assay and protein levels were assessed via western blot analysis. Patients with BAG1‑positive expression were revealed to have a prolonged survival time (progression‑free survival, 24.0 months) compared with that of patients without BAG1 expression (21.6 months; χ2=18.018, P<0.05). Treatment of A549 cells with tunicamycin followed by cisplatin resulted in elevated BAG1 levels. In addition, tunicamycin was found to significantly enhance cisplatin‑induced growth inhibition and apoptosis in A549 cells. The results indicate that BAG1 is important in cisplatin‑induced cell death in lung adenocarcinoma, suggesting that endoplasmic reticulum stress may promote the sensitivity of NSCLC patients to chemotherapy.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R and Gridelli C: Treatment of advanced non small cell lung cancer. J Thorac Dis. 3:122–133. 2011.PubMed/NCBI
3	Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in China, 2003-2005: A population-based study. Int J Cancer. 136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
4	Waters JS and O'Brien ME: The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of the national institute of clinical excellence (NICE). Br J Cancer. 87:481–490. 2002. View Article : Google Scholar : PubMed/NCBI
5	Fernet M and Hall J: Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst). 3:1237–1243. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ulrich CM, Robien K and McLeod HL: Cancer pharmacogenetics, Polymorphisms, pathways and beyond. Nat Rev Cancer. 3:912–920. 2003. View Article : Google Scholar : PubMed/NCBI
7	Townsend PA, Cutress RI, Sharp A, Brimmell M and Packham G: BAG-1: A multifunctional regulator of cell growth and survival. Biochim Biophys Acta. 1603:83–98. 2003.PubMed/NCBI
8	Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA and Reed JC: Cloning and functional analysis of BAG-1G1: A novel Bcl-2-binding protein with anti-cell death activity. Cell. 80:279–284. 1995. View Article : Google Scholar : PubMed/NCBI
9	Townsend PA, Stephanou A, Packham G and Latchman DS: BAG-1G1: A multi-functional pro-survival molecule. Int J Biochem Cell Biol. 37:251–259. 2005. View Article : Google Scholar : PubMed/NCBI
10	Yang L, McBurney D, Tang SC, Carlson SG and Horton WE Jr: A novel role for Bcl-2 associated-athanogene-1 (Bag-1) in regulation of the endoplasmic reticulum stress response in mammalian chondrocytes. J Cell Biochem. 102:786–800. 2007. View Article : Google Scholar : PubMed/NCBI
11	Rorke S, Murphy S, Khalifa M, Chernenko G and Tang SC: Prognostic significance of BAG-1 expression in nonsmall cell lung cancer. Int J Cancer. 95:317–322. 2001. View Article : Google Scholar : PubMed/NCBI
12	Liu H, Bai Y, Liu B, Wang Z, Wang M, Zhou Q and Chen J: The expression of BAG-1 and its clinical significance in human lung cancer. Zhongguo Fei Ai Za Zhi. 11:489–494. 2008.(In Chinese). PubMed/NCBI
13	Gotz R, Kramer BW, Camarero G and Rapp UR: BAG-1 haplo-insufficiency impairs lung tumorigenesis. BMC Cancer. 4:852004. View Article : Google Scholar : PubMed/NCBI
14	Greene FL, Page DL, Fritz AG, et al: Lung. AJCC Cancer Staging Manual (6th). (New York, NY). Springer. 170–171. 2001.
15	Karnofsky DA and Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of Chemotherapeutic Agents. MacLeod CM: (New York, NY). Columbia University Press. 191–205. 1949.
16	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. Histopathology. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
17	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
18	Xu C, Bailly-Maitre B and Reed JC: Endoplasmic reticulum stress, Cell life and death decisions. J Clin Invest. 115:2656–2664. 2005. View Article : Google Scholar : PubMed/NCBI
19	Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA and Yuan J: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 403:98–103. 2000. View Article : Google Scholar : PubMed/NCBI
20	Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
21	Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS and Christiani DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 22:2594–2601. 2004. View Article : Google Scholar : PubMed/NCBI
22	Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, Morris J and Thatcher N: Xeroderma pigmentosum group D haplotype predicts for response, survival and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 106:2421–2427. 2006. View Article : Google Scholar : PubMed/NCBI
23	Kim SH, Juhnn YS and Song YS: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann NY Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
24	Matakidou A, El Galta R, Webb EL, Rudd MF, Bridle H, Gelcaps Consortium, Eisen T and Houlston RS: Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 16:2333–2340. 2007. View Article : Google Scholar : PubMed/NCBI
25	Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D and Spitz MR: Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 18:955–965. 2008. View Article : Google Scholar : PubMed/NCBI
26	Liu H, Bai Y, Liu B, Wang Z, Wang M, Zhou Q and Chen J: The expression of BAG-1 and its clinical significance in human lung cancer. Zhongguo Fei Ai Za Zhi. 11:489–494. 2008.PubMed/NCBI
27	Morishima N, Nakanishi K, Takenouchi H, Shibata T and Yasuhiko Y: An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Histopathology. J Biol Chem. 277:34287–34294. 2002. View Article : Google Scholar : PubMed/NCBI
28	Tan Y, Dourdin N, Wu C, De Veyra T, Elce JS and Greer PA: Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis. J Biol Chem. 281:16016–16024. 2006. View Article : Google Scholar : PubMed/NCBI